Efficient repair of DNA double-strand breaks in malignant cells with structural instability.
Aberrant repair of DNA double-strand breaks (DSBs) is thought to be important in the generation of gross chromosomal rearrangements (GCRs). To examine how DNA DSBs might lead to GCRs, we investigated the repair of a single DNA DSB in a structurally unstable cell line. An I-SceI recognition site was introduced into OVCAR-8 cells between a constitutive promoter (EF1alpha) and the Herpes simplex virus thymidine kinase (TK) gene, which confers sensitivity to gancyclovir (GCV). Expression of I-SceI in these cells caused a single DSB. Clones with aberrant repair could acquire resistance to GCV by separation of the EF1alpha promoter from the TK gene, or deletion of either the EF1alpha promoter or the TK gene. All mutations that we identified were interstitial deletions. Treatment of cells with etoposide or bleomycin, agents known to produce DNA DSBs following expression of I-SceI also did not generate GCRs. Because we identified solely interstitial deletions using the aforementioned negative selection system, we developed a positive selection system to produce GCR. A construct containing an I-SceI restriction site immediately followed by a hygromycin phosphotransferase cDNA, with no promoter, was stably integrated into OVCAR-8 cells. DNA DSBs were produced by an I-SceI expression vector. None of the hygromycin resistant clones recovered had linked the hygromycin phosphotransferase cDNA to an endogenous promoter, but had instead captured a portion of the I-SceI expression vector. These results indicate that even in a structurally unstable malignant cell line, the majority of DNA DSBs are repaired by religation of the two broken chromosome ends, without the introduction of a GCR.
Cheng
Yue
Y
Genetics Branch, National Cancer Institute, Bethesda, MD 20889-5105, USA.
Zhang
Zhenhua
Z
Keenan
Bridget
B
Roschke
Anna V
AV
Nakahara
Kenneth
K
Aplan
Peter D
PD
D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D000998:Antiviral Agents / Q000494:pharmacology; D015139:Blotting, Southern; D002869:Chromosome Aberrations; D020223:Chromosome Painting; D002934:Cinnamates / Q000494:pharmacology; D053903:DNA Breaks, Double-Stranded; D004260:DNA Repair / Q000235:genetics*; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D005047:Etoposide / Q000494:pharmacology; D005260:Female; D015774:Ganciclovir / Q000494:pharmacology; D006801:Humans; D006921:Hygromycin B / Q000031:analogs & derivatives / Q000494:pharmacology; D017404:In Situ Hybridization, Fluorescence; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000473:pathology*; D020648:Peptide Elongation Factor 1 / Q000235:genetics; D017853:Phosphotransferases (Alcohol Group Acceptor) / Q000378:metabolism; D010957:Plasmids; D011401:Promoter Regions, Genetic / Q000235:genetics; D013937:Thymidine Kinase / Q000235:genetics; D014407:Tumor Cells, Cultured
D000972:Antineoplastic Agents, Phytogenic; D000998:Antiviral Agents; D002934:Cinnamates; D020648:Peptide Elongation Factor 1; D006921:Hygromycin B; C026273:hygromycin A; D005047:Etoposide; D017853:Phosphotransferases (Alcohol Group Acceptor); C063242:hygromycin-B kinase; D013937:Thymidine Kinase; D015774:Ganciclovir